Abstract
Summary
Rheumatoid arthritis (RA) patients had a higher risk of developing low bone mineral density (BMD) or osteoporosis. RA patients on classic disease-modifying antirheumatic drug (c-DMARD) therapy showed significantly lower BMD than controls, while no significant differences in most parameters were found between RA patients receiving biological disease-modifying antirheumatic drugs (b-DMARDs) and controls. The 3D analysis allowed us to find changes in the trabecular and cortical compartments.
Introduction
To evaluate cortical and trabecular bone involvement of the hip in RA patients by dual-energy X-ray absorptiometry (DXA) and 3D analysis. The secondary end-point was to evaluate bone involvement in patients treated with classic (c-DMARD) or biological (b-DMARD) disease-modifying antirheumatic drug therapies and the effect of the duration of the disease and corticosteroid therapy on 3D parameters.
Methods
A cross-sectional study of 105 RA patients and 100 subjects as a control group (CG) matched by age, sex, and BMI was carried out. BMD was measured by DXA of the bilateral femoral neck (FN) and total hip (TH). The 3D analyses including trabecular and cortical BMD were performed on hip scans with the 3D-Shaper software.
Results
FN and TH BMD and trabecular and cortical vBMD were significantly lower in RA patients. The c-DMARD (n = 75) group showed significantly lower trabecular and cortical vBMD than the CG. Despite the lower values, the b-DMARD group (n = 30) showed no significant differences in most parameters compared with the CG. The trabecular and cortical 3D parameters were significantly lower in the group with an RA disease duration of 1 to 5 years than in the CG, and the trabecular vBMD was significantly lower in the group with a duration of corticosteroid therapy of 1 to 5 years than in the CG, while no significant differences were found by standard DXA in the same period.
Conclusions
RA patients had a higher risk of developing low BMD or osteoporosis than controls. RA patients receiving c-DMARD therapy showed significantly lower BMD than controls, while no significant differences in most parameters were found between RA patients receiving b-DMARDs and controls. 3D-DXA allowed us to find changes in trabecular and cortical bone compartments in RA patients.
Similar content being viewed by others
References
Fassio A, Idolazzi L, Jaber MA, Dartizio C, Viapiana O, Rossini M, Gatti D (2016) The negative bone effects of the disease and of chronic corticosteroid treatment in premenopausal women affected by rheumatoid arthritis. Reumatismo 68:65–71
Firestein GS (2003) Evolving concepts of rheumatoid arthritis. Nature 423:356–361
Straub RH, Cutolo M, Pacifici R (2015) Evolutionary medicine and bone loss in chronic inflammatory diseases—a theory of inflammation-related osteopenia. Semin Arthritis Rheum 45:220–228
McInnes IB, Schett G (2011) The pathogenesis of rheumatoid arthritis. N Engl J Med 365:2205–2219
Güler-Yüksel M, Allaart CF, GoekoopRuiterman YPM et al (2009) Changes in hand and generalised bone mineral density in patients with recent-onset rheumatoid arthritis. Ann Rheum Dis 68:330–336
Gough AK, Peel NF, Eastell R, Holder RL, Lilley J, Emery P (1994) Excretion of pyridinium crosslinks correlates with disease activity and appendicular bone loss in early rheumatoid arthritis. Ann Rheum Dis 53:14–17
Gillespie MT (2007) Impact of cytokines and T lymphocytes upon osteoclast differentiation and function. Arthritis Res Ther 92:103
Lacativa PG, Farias ML (2010) Osteoporosis and inflammation. Arq Bras Endocrinol Metabol 54:123–132
van Staa TP, Leufkens HG, Abenhaim L, Zhang B, Cooper C (2000) Oral corticosteroids and fracture risk: relationship to daily and cumulative doses. Rheumatology (Oxford) 39:1383–1389
Dolan AL, Moniz C, Abraha H, Pitt P (2002) Does active treatment of rheumatoid arthritis limit disease-associated bone loss? Rheumatology (Oxford) 41:1047–1051
Wheater G, Elshahaly M, Naraghi K, Tuck SP, Datta HK, van Laar JM (2018) Changes in bone density and bone turnover in patients with rheumatoid arthritis treated with rituximab, results from an exploratory, prospective study. PLoS One 13:e0201527
Killinger Z, Gajdarova L, Kuzma M, Krajcovicova A, Brazdilova K, Jackuliak P, Payer J (2018) Biologic treatment in comparison to methotrexate has positive effect on trabecular bone score in rheumatoid arthritis patients: 1-year follow-up. Acta Clin Belg 74:121–125
Zerbini CAF, Clark P, Mendez-Sanchez L et al (2017) Biologic therapies and bone loss in rheumatoid arthritis. Osteoporos Int 28:429–446
Siris ES, Chen YT, Abbott TA, Barrett-Connor E, Miller PD, Wehren LE, Berger ML (2004) Bone mineral density thresholds for pharmacological intervention to prevent fractures. Arch Intern Med 164:1108–1112
Schuit SC, van der Klift M, Weel AE, de Laet CE, Burger H, Seeman E, Hofman A, Uitterlinden AG, van Leeuwen J, Pols HA (2004) Fracture incidence and association with bone mineral density in elderly men and women: the Rotterdam Study. Bone 34:195–202
Bouxsein ML, Delmas PD (2008) Considerations for development of surrogate endpoints for antifracture efficacy of new treatments in osteoporosis: a perspective. J Bone Miner Res 23:1155–1167
Cheng XG, Lowet G, Boonen S, Nicholson PH, Brys P, Nijs J, Dequeker J (1997) Assessment of the strength of proximal femur in vitro: relationship to femoral bone mineral density and femoral geometry. Bone 20:213–218
Clotet J, Martelli Y, Di Gregorio S, Del Río Barquero LM, Humbert L (2018) Structural parameters of the proximal femur by 3-dimentional dual-energy X-ray absorptiometry software: comparison with quantitative computed tomography. J Clin Densitom 21(4):550–562
Humbert L, Winzenrieth R, Di Gregorio S, Thomas T, Vico L, Malouf J, Del Río Barquero LM (2019) 3D analysis of cortical and trabecular bone from hip DXA: precision and trend assessment interval in postmenopausal women. J Clin Densitom 22(2):214–218
Humbert L, Martelli Y, Fonolla R, Steghofer M, Di Gregorio S, Malouf J, Romera J, Barquero LM (2017) 3D-DXA: assessing the femoral shape, the trabecular macrostructure and the cortex in 3D from DXA images. IEEE Trans Med Imaging 36:27–39
Brance ML, Di Gregorio S, Pons-Estel BA, Quagliato NJ, Jorfen M, Berbotto G, Cortese N, Raggio JC, Palatnik M, Chavero I, Soldano J, Wong R, Del Rio L, Sánchez A, Brun LR (2020) Prevalence of sarcopenia and whole-body composition in rheumatoid arthritis. J Clin Rheumatol. https://doi.org/10.1097/RHU.0000000000001549
Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3rd, Birnbaum NS, Burmester GR, Bykerk VP, Cohen MD, Combe B, Costenbader KH, Dougados M, Emery P, Ferraccioli G, Hazes JM, Hobbs K, Huizinga TW, Kavanaugh A, Kay J, Kvien TK, Laing T, Mease P, Ménard HA, Moreland LW, Naden RL, Pincus T, Smolen JS, Stanislawska-Biernat E, Symmons D, Tak PP, Upchurch KS, Vencovský J, Wolfe F, Hawker G (2010) Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 62:2569–2581
Fransen J, van Riel PL (2005) The Disease Activity Score and the EULAR response criteria. Clin Exp Rheumatol 23:S93–S99
van Gestel AM, Haagsma CJ, van Riel PL (1998) Validation of rheumatoid arthritis improvement criteria that include simplified joint counts. Arthritis Rheum 41:1845–1850
Shuhart CR, Yeap SS, Anderson PA, Jankowski LG, Lewiecki EM, Morse LR, Rosen HN, Weber DR, Zemel BS, Shepherd JA (2019) Executive summary of the 2019 ISCD Position Development Conference on Monitoring Treatment, DXA Cross-calibration and Least Significant Change, Spinal Cord Injury, Periprosthetic and Orthopedic Bone Health, Transgender Medicine, and Pediatrics. J Clin Densitom 22(4):453–471
Kanis JA, Oden A, Johnell O, Johansson H, de Laet C, Brown J, Burckhardt P, Cooper C, Christiansen C, Cummings S, Eisman JA, Fujiwara S, Glüer C, Goltzman D, Hans D, Krieg MA, la Croix A, McCloskey E, Mellstrom D, Melton LJ 3rd, Pols H, Reeve J, Sanders K, Schott AM, Silman A, Torgerson D, van Staa T, Watts NB, Yoshimura N (2007) The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women. Osteoporos Int 18:1033–1046
Kanis JA, Johansson H, Oden A, McCloskey EV (2011) Guidance for the adjustment of FRAX according to the dose of glucocorticoids. Osteoporos Int 22(3):809–816
R Development Core Team (2011) R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna ISBN 3-900051-07-0, URL http://www.R-project.org/
Haugeberg G, Conaghan PG, Quinn M, Emery P (2009) Bone loss in patients with active early rheumatoid arthritis: infliximab and methotrexate compared with methotrexate treatment alone. Explorative analysis from a 12-month randomised, double-blind, placebo-controlled study. Ann Rheum Dis 68:1898–1901
Haugeberg G, Uhlig T, Falch JA, Halse JI, Kvien TK (2000) Bone mineral density and frequency of osteoporosis in female patients with rheumatoid arthritis: results from 394 patients in the Oslo County Rheumatoid Arthritis register. Arthritis Rheum 43:522–553
Minaur NJ, Kounali D, Vedi S, Compston JE, Beresford JN, Bhalla AK (2002) Methotrexate in the treatment of rheumatoid arthritis. II. In vivo effects on bone mineral density. Rheumatology (Oxford) 41:741–749
Tascioglu F, Oner C, Armagan O (2003) The effect of low-dose methotrexate on bone mineral density in patients with early rheumatoid arthritis. Rheumatol Int 23:231–235
Wijbrandts CA, Klaasen R, Dijkgraaf MG, Gerlag DM, van Eck-Smit BL, Tak PP (2009) Bone mineral density in rheumatoid arthritis patients 1 year after adalimumab therapy: arrest of bone loss. Ann Rheum Dis 68:373–376
Vis M, Havaardsholm EA, Haugeberg G, Uhlig T, Voskuyl AE, van de Stadt R, Dijkmans BA, Woolf AD, Kvien TK, Lems WF (2006) Evaluation of bone mineral density, bone metabolism, osteoprotegerin and receptor activator of the NFkb ligand serum levels during treatment with infliximab in patients with rheumatoid arthritis. Ann Rheum Dis 65:1495–1499
Haugeberg G, Helgetveit KB, Førre Ø, Garen T, Sommerseth H, Prøven A (2014) Generalized bone loss in early rheumatoid arthritis patients followed for ten years in the biologic treatment era. BMC Musculoskelet Disord 15:289
Winzenrieth R, Humbert L, Di Gregorio S, Bonel E, García M, Del Rio L (2018) Effects of osteoporosis drug treatments on cortical and trabecular bone in the femur using DXA-based 3D modeling. Osteoporos Int 29:2323–2333
Humbert L, Bagué A, Di Gregorio S, Winzenrieth R, Sevillano X, González Ballester MÁ, Del Rio L (2018) DXA-based 3D analysis of the cortical and trabecular bone of hip fracture postmenopausal women: a case-control study. J Clin Densitom S1094-6950(18):30209–30209
Shibuya K, Hagino H, Morio Y, Teshima R (2002) Cross-sectional and longitudinal study of osteoporosis in patients with rheumatoid arthritis. Clin Rheumatol 21:150–158
van Staa TP, Leufkens HG, Cooper C (2002) The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int 13(10):777–787
Acknowledgments
The authors would like to acknowledge Naraline Luna Meneses, Agustín Razzini, Julieta Miljevic, Joaquín Percudani, and Pilar Rubio for technical assistance.
Funding
This work was supported by a Pan American League of Associations for Rheumatology (PANLAR) Award to MLB and grants from the Argentine Society of Rheumatology (SARFILINE) and Fundación Roemmers to MLB and Rosario National University to LRB.
Author information
Authors and Affiliations
Contributions
Study design: MLB and LRB. Patient and data acquisition: MLB, BAPE, NJQ, MJ, GB, NC, JCR, MP, IC, JS, and CD. Data analysis: MLB, AS, SDG, and LRB. Data interpretation and drafting of manuscript: MLB, AS, LDR, SDG, and LRB. All authors read and approved the final manuscript.
Corresponding author
Ethics declarations
Conflicts of interest
None.
Ethics approval information
The Ethics Committee of the School of Medicine, Rosario National University (Argentina) (1MED486), approved the study in accordance with the Declaration of Helsinki.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Brance, M., Pons-Estel, B., Quagliato, N. et al. Trabecular and cortical bone involvement in rheumatoid arthritis by DXA and DXA-based 3D modelling. Osteoporos Int 32, 705–714 (2021). https://doi.org/10.1007/s00198-020-05641-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00198-020-05641-4